生物制药公司Ardelyx（股票代码：ARDX）周五盘中股价暴跌25.94%，创下近期新低。这一大幅下跌主要源于公司发布的2025年第一季度财报未能达到分析师预期，引发投资者对公司短期业绩的担忧。
根据Ardelyx公布的财报，截至3月31日的第一季度，公司调整后每股亏损17美分，远低于分析师平均预期的11美分亏损。虽然季度营收同比增长61%达到7411万美元，但仍未达到市场预期的7880万美元。此外，公司报告当季净亏损4114万美元，这些数据均显示公司业绩表现不如预期。
值得注意的是，尽管本次财报表现不佳导致股价大跌，但Ardelyx股价在过去一个季度曾上涨12.1%，今年迄今为止累计上涨8.6%。分析师对该公司的平均评级仍维持在"买入"，12个月目标价中位数为11.00美元。然而，投资者似乎对公司短期业绩表现感到失望，导致股价出现如此大幅度的下跌。未来Ardelyx能否改善业绩表现，将成为市场关注的焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.